

Supplementary Online Content

De Giorgi V, Grazzini M, Benemei S, Marchionni N, Botteri E, Pennacchioli E, Geppetti P, Gandini S. Propranolol for off-label treatment of patients with melanoma: results from a cohort study. *JAMA Onc.* doi:10.1001/jamaoncol.2017.2908

eTable 1. Inclusion and exclusion criteria

eTable 2. Main clinical and histopathological characteristics of the study population based β -blocker treatment status

This supplementary material has been provided by the authors to give readers additional information about their work.

ONLINE-ONLY SUPPLEMENT

eTable 1 : Inclusion and exclusion criteria.

eTable 2 : Main clinical and histopathological characteristics of the study population based β -blocker treatment status

eTable 1 : Inclusion and exclusion criteria.

<u>Inclusion criteria</u>
1. 18-75 years old with newly diagnosed histologically proven resected melanoma;
2. Stage: Ib (T1b, T2a), IIa (T2b, T3a), IIb (T3b T4a) and IIc (T4b), N0, M0; IIIA (N1a, N1b)
3. Signed Informed Consent;
<u>Exclusion criteria</u>
1. Presence of metastasis
2. Clinical/radiological evidence or laboratory/pathology report of not completely resected melanoma;
3. History of cancer
4. Current use or past use in the last two years of any β -blockers for any medical condition
5. Contraindication to the use of propranolol

eTable 2 : Main clinical and histopathological characteristics of the study population based β -blocker treatment status

	PROP N=19	No-PROP N=34	P-value
Male gender, n. (%)	11 (57.9%)	22 (64.7%)	0.62
Age, Median and IQR	58 (49, 78)	66 (47, 75)	0.88
Breslow thickness, Median and IQR	2.8 (1.8, 4.3)	2.6 (1.6, 4.0)	0.54
Melanoma stage			0.24
Ib	2 (10,5%)	9 (26,5%)	
Ila	5 (26,4%)	8 (23,5%)	
Iib	5 (26,4%)	5 (14,8%)	
Iic	4 (21,0%)	6 (17,6%)	
Illa	3 (15,7%)	6 (17,6%)	
Sentinel lymph-node involvement			0.67
No, n. (%)	7 (39%)	15 (44%)	
Yes, n. (%)	3 (17%)	6 (18%)	
Not Performed, n. (%)	8 (44%)	13 (38%)	
Site of primary melanoma			0.19
Head or neck, n. (%)	6 (32%)	4 (12%)	
Trunk, n. (%)	4 (21%)	16 (47%)	
Upper limbs, n. (%)	4 (21%)	6 (17%)	
Lower limbs, n. (%)	5 (26%)	8 (24%)	
Histology			0.32
SSM, n. (%)	7 (37%)	21 (62%)	
Nodular, n. (%)	7 (37%)	12 (35%)	
Other	5 (26%)	1 (3%)	
Lesion with ulceration			0.05
No, n. (%)	7 (37%)	22 (65%)	
Yes, n. (%)	12 (63%)	12 (35%)	
Number of mitosis			0.25
0, n. (%)	2 (11%)	1 (3%)	
>0, n. (%)	17 (89%)	33 (97%)	
Patients with hypertension			0.19
No, n. (%)	13 (68%)	17 (50%)	
Yes, n. (%)	6 (32%)	17 (50%)	
ACEi or aspirin use			0.28
No, n. (%)	14 (74%)	20 (59%)	
Yes, n. (%)	5 (26%)	14 (41%)	
Events during follow-up			
Recurrences, n. (%)	3 (16%)	14 (41%)	0.06
Deaths, n. (%)	2 (11%)	6 (18%)	0.49

P-value from Chi-square or Fisher Exact tests, as appropriate